纯红细胞再生障碍性贫血67例临床分析
本研究为多中心回顾性临床研究,纳入2010年6月1日至2019年6月1日初诊的18岁以上纯红细胞再生障碍性贫血(PRCA)患者67例,分析继发因素、实验室特点、治疗方案及预后。继发性PRCA占44.8%(30/67),最常见为胸腺瘤(10例)和T细胞大颗粒淋巴细胞白血病(6例);总缓解率85.7%,3年总体生存率(74.3±7.5)%。单用环孢素A缓解率稍高于单用激素或联合糖皮质激素[90.0%(36/40)对75.0%(12/16),P=0.147]。
要点
- 继发性PRCA占44.8%(30/67),最常见基础疾病为胸腺瘤(10例)和T细胞大颗粒淋巴细胞白血病(6例)。
- PRCA总缓解率85.7%,3年总体生存率(74.3±7.5)%。
- 环孢素A减量间隔≥1个月组中位无病生存未达到,长于减量间隔<1个月组的15(95% CI 7~23)个月(P<0.001)。
核心结论
- PRCA可发生于多种疾病,缓解率与生存率高,单用环孢素A治疗效果好,起效且稳定后需缓慢减量以降低复发率。
研究设计与样本
- 本研究为多中心回顾性临床研究,纳入2010年6月1日至2019年6月1日初诊的18岁以上PRCA患者进行随访。
- 共纳入67例PRCA患者,根据患者采用的不同治疗方案及不同药物减量速度进行缓解率与总体生存率的比较分析。
主要发现
- 继发性PRCA占44.8%(30/67),最常见的基础疾病为胸腺瘤(10例)和T细胞大颗粒淋巴细胞白血病(6例)。
- PRCA患者总缓解率(ORR)为85.7%,3年总体生存(OS)率为(74.3±7.5)%。
- 单用环孢素A治疗缓解率为90.0%(36/40),单用激素或环孢素A联合糖皮质激素为75.0%(12/16),两组比较P=0.147。
- 环孢素A治疗达完全缓解或部分缓解3~6个月后每次减量25 mg/d,减量间隔≥1个月组中位无病生存未达到,减量间隔<1个月组为15(95% CI 7~23)个月,P<0.001。
- 有62.5%(10/16)患者复发后按初始治疗方案或增加剂量再次治疗仍有效。
关键数值与推荐
- PRCA总缓解率85.7%,3年总体生存率(74.3±7.5)%。
- 单用环孢素A缓解率90.0%(36/40)对单用激素或联合糖皮质激素75.0%(12/16),P=0.147。
- 环孢素A减量间隔≥1个月组中位无病生存未达到对减量间隔<1个月组15(95% CI 7~23)个月,P<0.001。
- 复发后按初始治疗方案或增加剂量再次治疗有效率为62.5%(10/16)。
临床怎么用
- 作者认为单用环孢素A治疗效果好,可作为首选。
- 作者建议环孢素A起效且患者达到稳定状态后需缓慢减量以降低复发率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate secondary factors, laboratory features, treatment options, and prognosis of pure red cell aplastic anemia (PRCA) . Methods: This was a multicenter retrospective clinical study. Patients aged above 18 years newly diagnosed with PRCA between June 1, 2010, and June 1, 2019, were recruited as the main study object. A comparative analysis of remission rate and overall survival rate was made according to different treatment schemes adopted by patients and different drug reduction rates. Results: A total of 67 patients with PRCA were included in this study and the secondary PRCA group accounted for 44.8% (30/67) . The most common secondary factors were thymoma (n=10) and T-cell large lymphocytic leukemia (T-LGLL) (n=6) . The overall response rate of PRCA was 85.7% and the 3-year overall survival rate of PRCA was (74.3±7.5) %. The remission rate of cyclosporine A alone was slightly higher than that of oral glucocorticoid alone or combined with glucocorticoid[90.0% (36/40) vs 75.0% (12/16) , P=0.147]. After patients applied with cyclosporine A treatment reached CR/PR and remained stable for 3-6 months, the dose of cyclosporine A was reduced by 25 mg each time. The cyclosporine A reduction interval of a 25 mg/d reduction in more than 1 month significantly prolonged the median disease-free survival compared with a 25 mg/d reduction in less than 1 month [not reached vs 15 (95% CI 7-23) months, P<0.001]. There were 62.5% (10/16) of patients who responded to the initial or incremental treatment regimen after relapse. Conclusion: PRCA has features of various secondary factors, high overall survival rate, and high remission rate. Treatment with cyclosporine A alone is preferred, and cyclosporine A should be slowly tapered to reduce the risk of later relapse after it takes effect and patients reach a steady state. 目的: 总结纯红细胞再生障碍(PRCA)的继发因素、实验室特点、治疗方案及预后。 方法: 本研究为多中心回顾性临床研究,纳入2010年6月1日至2019年6月1日初诊的18岁以上PRCA患者进行随访,并根据不同治疗方案与药物减量速度等进行疗效、生存的比较分析。 结果: 共纳入67例PRCA患者,其中继发性PRCA占44.8%(30/67),最常见的基础疾病为胸腺瘤(10例)和T细胞大颗粒淋巴细胞白血病(6例)。PRCA患者总缓解率(ORR)为85.7%,3年总体生存(OS)率为(74.3±7.5)%。单用环孢素A治疗缓解率稍高于单用激素或环孢素A联合糖皮质激素[90.0%(36/40)对75.0%(12/16),P=0.147]。环孢素A治疗达完全缓解或部分缓解3~6个月后,每次减量25 mg/d,减量间隔≥1个月组中位无病生存时间长于减量间隔<1个月组[未达到对15(95% CI 7~23)个月,P<0.001]。有62.5%(10/16)患者复发后按初始治疗方案或增加剂量再次治疗仍有效。 结论: PRCA可发生于多种疾病,缓解率与生存率高,单用环孢素A治疗效果好,起效且稳定后需缓慢减量以降低复发率。.
引用
- Wang Q, Ma JX, Li BH, et al. [Clinical analysis of 67 cases of pure red cell aplastic anemia]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32654466. doi:10.3760/cma.j.issn.0253-2727.2020.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。